Related references
Note: Only part of the references are listed.Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit
Rashmi R. Shah et al.
DRUG SAFETY (2015)
Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia
Javid J. Moslehi et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Cancer-Associated Venous Thromboembolic Disease, Version 1.2015 Featured Updates to the NCCN Guidelines
Michael B. Streiff et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)
Bevacizumab Increases the Risk of Severe Congestive Heart Failure in Cancer Patients: An Up-to-Date Meta-Analysis with a Focus on Different Subgroups
Wei-Xiang Qi et al.
CLINICAL DRUG INVESTIGATION (2014)
Hypertension as a Risk Factor for Heart Failure
Arun Kannan et al.
CURRENT HYPERTENSION REPORTS (2014)
The Accelerated Approval of Oncologic Drugs Lessons From Ponatinib
Vinay Prasad et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
2014 Evidence-based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) (vol 311, pg 507, 2014)
P. A. James
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs et al.
LANCET (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)
Paul A. James et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials
W. -X. Qi et al.
ANNALS OF ONCOLOGY (2013)
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Wei-Xiang Qi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials
Guru Sonpavde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors
Manuela Schmidinger
EJC SUPPLEMENTS (2013)
Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: A systematic review and meta-analysis
Kashif Kalam et al.
EUROPEAN JOURNAL OF CANCER (2013)
Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
Wei-Xiang Qi et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
D. Farge et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2013)
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib
T. D. Kim et al.
LEUKEMIA (2013)
Vascular endothelial growth factor in heart failure
Ziad Taimeh et al.
NATURE REVIEWS CARDIOLOGY (2013)
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
Herbert I. Hurwitz et al.
ONCOLOGIST (2013)
Analysis of Early Hypertension and Clinical Outcome With Bevacizumab: Results From Seven Phase III Studies
Herbert I. Hurwitz et al.
ONCOLOGIST (2013)
Gene Therapy to Treat Cardiovascular Disease
Julie A. Wolfram et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2013)
Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1
Nilka de Jesus-Gonzalez et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts
M. Reck et al.
ANNALS OF ONCOLOGY (2012)
Management of Antiangiogenic Therapy-Induced Hypertension
Nilka de Jesus-Gonzalez et al.
HYPERTENSION (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
Joseph M. Gozgit et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
Sophie Leboulleux et al.
LANCET ONCOLOGY (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis
Jiajie Zang et al.
PLOS ONE (2012)
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes
F. A. B. Schutz et al.
ANNALS OF ONCOLOGY (2011)
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab
N. C. Tebbutt et al.
ANNALS OF ONCOLOGY (2011)
Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists
Stephane Ederhy et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
Xiao Feng Hang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Bevacizumab and Heart Failure Risk in Patients With Breast Cancer: A Thorn in the Side?
Nitin Verma et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Reversible Cardiomyopathy Associated with Sunitinib and Sorafenib
Imran Uraizee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
Vishal Ranpura et al.
ACTA ONCOLOGICA (2010)
Vascular endothelial growth factors and vascular permeability
David O. Bates
CARDIOVASCULAR RESEARCH (2010)
Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Patrizia Ferroni et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
Mao Mao An et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
Michael L. Maitland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
Lucio Crino et al.
LANCET ONCOLOGY (2010)
Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
Sanjaykumar Hapani et al.
ONCOLOGY (2010)
Management of hypertension in angiogenesis inhibitor-treated patients
H. Izzedine et al.
ANNALS OF ONCOLOGY (2009)
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study
Mark Kozloff et al.
ONCOLOGIST (2009)
Response to Sorafenib After Sunitinib-Induced Acute Heart Failure in a Patient with Metastatic Renal Cell Carcinoma: Case Report and Review of the Literature
Michael K. K. Wong et al.
PHARMACOTHERAPY (2009)
Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
Shobha Rani Nalluri et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Manuela Schmidinger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
Frank A. Scappaticci et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Molecularly targeted oncology therapeutics and prolongation of the QT interval
Elizabeth L. Strevel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of adverse effects of anti-VEGF therapy for cancer
T. Kamba et al.
BRITISH JOURNAL OF CANCER (2007)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Vascular endothelial growth factor and angiogenesis
A Hoeben et al.
PHARMACOLOGICAL REVIEWS (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer
DH Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Management of bleeding in patients with advanced cancer
J Pereira et al.
ONCOLOGIST (2004)
Bevacizumab, bleeding, thrombosis, and warfarin
S Kilickap et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The biology of VEGF and its receptors
N Ferrara et al.
NATURE MEDICINE (2003)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
The role of nitric oxide in hypertension and renal disease progression
S Klahr
NEPHROLOGY DIALYSIS TRANSPLANTATION (2001)
Share Paper
